Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

The effect of EDTA-based chelation on patients with diabetes and peripheral artery disease in the Trial to Assess Chelation Therapy (TACT).

Ujueta F, Arenas IA, Escolar E, Diaz D, Boineau R, Mark DB, Golden P, Lindblad L, Kim H, Lee KL, Lamas GA.

J Diabetes Complications. 2019 Jul;33(7):490-494. doi: 10.1016/j.jdiacomp.2019.04.005. Epub 2019 Apr 14.

2.

Concussion management in combat sports: consensus statement from the Association of Ringside Physicians.

Neidecker J, Sethi NK, Taylor R, Monsell R, Muzzi D, Spizler B, Lovelace L, Ayoub E, Weinstein R, Estwanik J, Reyes P, Cantu RC, Jordan B, Goodman M, Stiller JW, Gelber J, Boltuch R, Coletta D, Gagliardi A, Gelfman S, Golden P, Rizzo N, Wallace P, Fields A, Inalsingh C.

Br J Sports Med. 2019 Mar;53(6):328-333. doi: 10.1136/bjsports-2017-098799. Epub 2018 Jul 26.

3.

Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome.

Fodor AA, Pimentel M, Chey WD, Lembo A, Golden PL, Israel RJ, Carroll IM.

Gut Microbes. 2019;10(1):22-33. doi: 10.1080/19490976.2018.1460013. Epub 2018 Jul 18.

4.

Case Report and Review of Management of Penetrating Trauma and Cardiac Pericarditis.

Thomas E, Golden P, Moran V.

J Trauma Nurs. 2017 May/Jun;24(3):174-181. doi: 10.1097/JTN.0000000000000287. Review.

PMID:
28486324
5.

A Transcriptional Lineage of the Early C. elegans Embryo.

Tintori SC, Osborne Nishimura E, Golden P, Lieb JD, Goldstein B.

Dev Cell. 2016 Aug 22;38(4):430-44. doi: 10.1016/j.devcel.2016.07.025.

6.

Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome.

Acosta A, Camilleri M, Shin A, Linker Nord S, O'Neill J, Gray AV, Lueke AJ, Donato LJ, Burton DD, Szarka LA, Zinsmeister AR, Golden PL, Fodor A.

Clin Transl Gastroenterol. 2016 May 26;7:e173. doi: 10.1038/ctg.2016.32.

7.

Assessment of public perception and environmental compliance at a pulp and paper facility: a Canadian case study.

Hoffman E, Bernier M, Blotnicky B, Golden PG, Janes J, Kader A, Kovacs-Da Costa R, Pettipas S, Vermeulen S, Walker TR.

Environ Monit Assess. 2015 Dec;187(12):766. doi: 10.1007/s10661-015-4985-5. Epub 2015 Nov 20.

PMID:
26590146
8.

Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis.

Rubin DT, Sandborn WJ, Bosworth B, Zakko S, Gordon GL, Sale ME, Rolleri RL, Golden PL, Barrett AC, Bortey E, Forbes WP.

Dig Dis Sci. 2015 Nov;60(11):3408-17. doi: 10.1007/s10620-015-3868-5. Epub 2015 Sep 19.

9.

Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis.

Sandborn WJ, Bosworth B, Zakko S, Gordon GL, Clemmons DR, Golden PL, Rolleri RL, Yu J, Barrett AC, Bortey E, Paterson C, Forbes WP.

Gastroenterology. 2015 Apr;148(4):740-750.e2. doi: 10.1053/j.gastro.2015.01.037. Epub 2015 Jan 30.

10.

Vasopressin decreases pulmonary-to-systemic vascular resistance ratio in a porcine model of severe hemorrhagic shock.

Sarkar J, Golden PJ, Kajiura LN, Murata LA, Uyehara CF.

Shock. 2015 May;43(5):475-82. doi: 10.1097/SHK.0000000000000325.

PMID:
25565637
11.

Pilot Trial of an Electronic Family Medical History in US Faith-Based Communities.

Newcomb P, Canclini S, Cauble D, Raudonis B, Golden P.

J Prim Care Community Health. 2014 Jul;5(3):198-201. doi: 10.1177/2150131914524441. Epub 2014 Feb 25.

PMID:
24569130
12.

Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a randomized, double-blind, placebo-controlled, two-stage study.

Macarthur RD, Hawkins TN, Brown SJ, Lamarca A, Clay PG, Barrett AC, Bortey E, Paterson C, Golden PL, Forbes WP.

HIV Clin Trials. 2013 Nov-Dec;14(6):261-73. doi: 10.1310/hct1406-261.

PMID:
24334179
13.

Percutaneous temporary aortic valve: a proof-of-concept animal model.

Ho PC, Nguyen ME, Golden PJ.

J Heart Valve Dis. 2013 Jul;22(4):460-7.

PMID:
24224407
14.

American Society for Apheresis white paper: considerations for medical staff apheresis medicine physician credentialing and privileging.

Andrzejewski C Jr, Linz W, Hofmann J, O'Doherty U, Robinson RS, Arepally GM, Golden P.

J Clin Apher. 2012;27(6):330-5. doi: 10.1002/jca.21250. Epub 2012 Nov 2.

PMID:
23124963
15.

Substituted tetrahydro-beta-carbolines as potential agents for the treatment of human papillomavirus infection.

Miller JF, Turner EM, Sherrill RG, Gudmundsson K, Spaltenstein A, Sethna P, Brown KW, Harvey R, Romines KR, Golden P.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):256-9. doi: 10.1016/j.bmcl.2009.10.123. Epub 2009 Oct 30.

PMID:
19914830
16.

Tetrahydrocarbazole amides with potent activity against human papillomaviruses.

Gudmundsson KS, Boggs SD, Sebahar PR, Richardson LD, Spaltenstein A, Golden P, Sethna PB, Brown KW, Moniri K, Harvey R, Romines KR.

Bioorg Med Chem Lett. 2009 Aug 1;19(15):4110-4. doi: 10.1016/j.bmcl.2009.06.001. Epub 2009 Jun 6.

PMID:
19556128
17.

Pharmacovirological impact of an integrase inhibitor on human immunodeficiency virus type 1 cDNA species in vivo.

Goffinet C, Allespach I, Oberbremer L, Golden PL, Foster SA, Johns BA, Weatherhead JG, Novick SJ, Chiswell KE, Garvey EP, Keppler OT.

J Virol. 2009 Aug;83(15):7706-17. doi: 10.1128/JVI.00683-09. Epub 2009 May 20.

18.

Synthesis and antiviral activity of 7-benzyl-4-hydroxy-1,5-naphthyridin-2(1H)-one HIV integrase inhibitors.

Boros EE, Edwards CE, Foster SA, Fuji M, Fujiwara T, Garvey EP, Golden PL, Hazen RJ, Jeffrey JL, Johns BA, Kawasuji T, Kiyama R, Koble CS, Kurose N, Miller WH, Mote AL, Murai H, Sato A, Thompson JB, Woodward MC, Yoshinaga T.

J Med Chem. 2009 May 14;52(9):2754-61. doi: 10.1021/jm801404b.

PMID:
19374386
19.

Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.

Sparks SM, Banker P, Bickett DM, Clancy DC, Dickerson SH, Garrido DM, Golden PL, Peat AJ, Sheckler LR, Tavares FX, Thomson SA, Weiel JE.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):981-5. doi: 10.1016/j.bmcl.2008.11.084. Epub 2008 Nov 27.

PMID:
19095443
20.

Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.

Sparks SM, Banker P, Bickett DM, Carter HL, Clancy DC, Dickerson SH, Dwornik KA, Garrido DM, Golden PL, Nolte RT, Peat AJ, Sheckler LR, Tavares FX, Thomson SA, Wang L, Weiel JE.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):976-80. doi: 10.1016/j.bmcl.2008.11.085. Epub 2008 Nov 27.

PMID:
19095442
21.

Amino acid anthranilamide derivatives as a new class of glycogen phosphorylase inhibitors.

Evans KA, Li YH, Coppo FT, Graybill TL, Cichy-Knight M, Patel M, Gale J, Li H, Thrall SH, Tew D, Tavares F, Thomson SA, Weiel JE, Boucheron JA, Clancy DC, Epperly AH, Golden PL.

Bioorg Med Chem Lett. 2008 Jul 15;18(14):4068-71. doi: 10.1016/j.bmcl.2008.05.102. Epub 2008 Jun 12.

PMID:
18554908
22.

Assisting states in planning for pandemic influenza.

Manderscheid RW, Golden PS, Smith CL.

Am J Disaster Med. 2007 Jan-Feb;2(1):5-8. No abstract available.

PMID:
18268868
23.
24.

Treatment of mercury intoxication with dimercaptopropanesulfonate.

Smith B, Golden P, Pingree C.

Int J Pharm Compd. 2005 Mar-Apr;9(2):105-8.

PMID:
23924910
25.

Bradycardia at low doses of risperidone.

Tran KT, Golden P, Lark T, Jacob NJ.

Am J Psychiatry. 2004 Dec;161(12):2325-6. No abstract available. Erratum in: Am J Psychiatry. 2007 Feb;164(2):351. Goldman, Peter [corrected to Golden, Peter].

PMID:
15569911
26.

Red wine and red wine polyphenolic compounds but not alcohol inhibit ADP-induced platelet aggregation.

De Lange DW, Van Golden PH, Scholman WL, Kraaijenhagen RJ, Akkerman JW, Van De Wiel A.

Eur J Intern Med. 2003 Oct;14(6):361-366.

PMID:
14769494
27.

Blood-brain barrier efflux transport.

Golden PL, Pollack GM.

J Pharm Sci. 2003 Sep;92(9):1739-53. Review.

PMID:
12949994
28.
29.

A nephrology based mobile extracorporeal therapy service.

Sweet R, Golden PJ.

Transfus Apher Sci. 2003 Apr;28(2):187-95.

PMID:
12679125
30.

Implementing a geriatric resource nurse model.

Lopez M, Delmore B, Ake JM, Kim YR, Golden P, Bier J, Fulmer T.

J Nurs Adm. 2002 Nov;32(11):577-85.

PMID:
12464775
31.

Hemapheresis listening post.

Golden PJ.

Transfus Apher Sci. 2002 Apr;26(2):111. No abstract available.

PMID:
12121065
32.

Topography of the neurotensin (NT)(8-9) binding site of human NT receptor-1 probed with NT(8-13) analogs.

Lundquist JT 4th, Büllesbach EE, Golden PL, Dix TA.

J Pept Res. 2002 Feb;59(2):55-61.

PMID:
11906607
33.

Adverse reactions associated with mobile therapeutic apheresis: analysis of 17,940 procedures.

Kiprov DD, Golden P, Rohe R, Smith S, Hofmann J, Hunnicutt J.

J Clin Apher. 2001;16(3):130-3.

PMID:
11746539
34.

Thoracic trauma.

Golden PA.

Orthop Nurs. 2000 Sep-Oct;19(5):37-45; quiz 45-7. Review.

PMID:
11153385
35.

Brain microvascular P-glycoprotein and a revised model of multidrug resistance in brain.

Golden PL, Pardridge WM.

Cell Mol Neurobiol. 2000 Apr;20(2):165-81. Review.

PMID:
10696508
37.

4-(1-benzoylindol-3-yl)butyric acids and FK143: novel nonsteroidal inhibitors of steroid 5 alpha-reductase (II).

Sawada K, Okada S, Golden P, Kayakiri N, Sawada Y, Hashimoto M, Tanaka H.

Chem Pharm Bull (Tokyo). 1999 Apr;47(4):481-91.

PMID:
10319427
38.

Chylothorax in blunt trauma: a case report.

Golden P.

Am J Crit Care. 1999 May;8(3):189-92. Review. No abstract available.

PMID:
10228660
39.

P-Glycoprotein on astrocyte foot processes of unfixed isolated human brain capillaries.

Golden PL, Pardridge WM.

Brain Res. 1999 Feb 20;819(1-2):143-6.

PMID:
10082869
40.

(1-Benzylindole-3-yl)alkanoic acids; novel nonsteroidal inhibitors of steroid 5 alpha-reductase (I).

Sawada K, Hirai H, Golden P, Okada S, Sawada Y, Hashimoto M, Tanaka H.

Chem Pharm Bull (Tokyo). 1998 Nov;46(11):1683-7.

PMID:
9890779
41.

Up-regulation of blood-brain barrier short-form leptin receptor gene products in rats fed a high fat diet.

Boado RJ, Golden PL, Levin N, Pardridge WM.

J Neurochem. 1998 Oct;71(4):1761-4.

42.

Rationale for influx enhancement versus efflux blockade to increase drug exposure to the brain.

Golden PL, Pollack GM.

Biopharm Drug Dispos. 1998 May;19(4):263-72.

PMID:
9604127
43.
44.

Treatment of large solid tumors in mice with daunomycin-loaded sterically stabilized liposomes.

Golden PL, Huwyler J, Pardridge WM.

Drug Deliv. 1998;5(3):207-12. doi: 10.3109/10717549809052036.

PMID:
19569986
45.

A computerized business simulation for dental practice management.

Willis DO, Smith JR, Golden P.

J Dent Educ. 1997 Oct;61(10):821-8.

PMID:
9385326
46.

Brain microvascular and astrocyte localization of P-glycoprotein.

Pardridge WM, Golden PL, Kang YS, Bickel U.

J Neurochem. 1997 Mar;68(3):1278-85.

47.
48.

Repair of laparoscopic injury to abdominal wall arteries complicated by cutaneous necrosis.

Spitzer M, Golden P, Rehwaldt L, Benjamin F.

J Am Assoc Gynecol Laparosc. 1996 May;3(3):449-52.

PMID:
9050673
49.

Thinking of working in New Zealand?

Golden P.

Midwives (1995). 1996 Apr;109(1299):90. No abstract available.

PMID:
8716364
50.

Serving our communities better. Guidelines for planning and developing integrated delivery networks.

Prybil L, Golden P, Ballance X.

Health Prog. 1995 Apr;76(3):34-7, 48.

PMID:
10141634

Supplemental Content

Loading ...
Support Center